12.01.17
Jabil announced that Christopher Holland has been nominated to stand for election to the Jabil Board of Directors in January 2018.
“Chris has been successful in both growing and transforming businesses within the services and healthcare sectors,” said Tim Main, Jabil’s chairman of the board. “I believe these experiences combined with his outstanding acumen in investment banking, finance, operations and strategy will make Chris a great addition to our board."
Holland has been SVP and CFO of C.R. Bard, Inc., a multinational developer, manufacturer and marketer of medical technologies and products, since May 2012. During his time at Bard, he has had responsibility for business development, corporate marketing, strategy, reimbursement and the Bard Medical Division. Before joining Bard, Holland was most recently SVP, finance and treasurer of Aramark Corporation. Prior to joining Aramark, Holland served as VP and medical device sector head at J. P. Morgan and Company, Inc.
The company also announced that Frank Newman has decided to retire from the Board at the time of the annual meeting in January and will not stand for re-election.
“On behalf of the Board and our Management Team, I’d like to thank Frank for his outstanding leadership over the past 20+ years,” said Jabil CEO Mark Mondello.
“Chris has been successful in both growing and transforming businesses within the services and healthcare sectors,” said Tim Main, Jabil’s chairman of the board. “I believe these experiences combined with his outstanding acumen in investment banking, finance, operations and strategy will make Chris a great addition to our board."
Holland has been SVP and CFO of C.R. Bard, Inc., a multinational developer, manufacturer and marketer of medical technologies and products, since May 2012. During his time at Bard, he has had responsibility for business development, corporate marketing, strategy, reimbursement and the Bard Medical Division. Before joining Bard, Holland was most recently SVP, finance and treasurer of Aramark Corporation. Prior to joining Aramark, Holland served as VP and medical device sector head at J. P. Morgan and Company, Inc.
The company also announced that Frank Newman has decided to retire from the Board at the time of the annual meeting in January and will not stand for re-election.
“On behalf of the Board and our Management Team, I’d like to thank Frank for his outstanding leadership over the past 20+ years,” said Jabil CEO Mark Mondello.
